Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Bayer develops CETP inhibitors

Dec. 4, 1997

Intermittent therapy with 5-HT reuptake inhibitor effective for dysphoric PMS

Dec. 3, 1997

Mechanism of renoprotective effects of ACE inhibitors in diabetic nephropathy

Dec. 3, 1997

Reduced PSF expression associated with development of vascular lesions

Dec. 3, 1997

Takeda discloses new series of prolactin secretion inhibitors

Dec. 3, 1997

Maillard reaction inhibitors from Kissei

Dec. 3, 1997

MAbs to lymphocyte/endothelial adhesion molecules prevent diabetes in mouse model

Dec. 2, 1997

Muse approved in U.K.

Dec. 2, 1997

Further labeling changes for Rezulin/Noscal; Romozin availability suspended in U.K.

Dec. 2, 1997

AHP describes new compounds with tissue-selective estrogenic and antiestrogenic effects

Dec. 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.